The Wall Street Journal Covers Engaged Capital’s Opposition to HeartWare’s Acquisition of Valtech
The Wall Street Journal covered the public opposition of Olshan activist client, Engaged Capital LLC, against HeartWare International Inc.’s proposed acquisition of Valtech Cardio Ltd. Engaged Capital, one of HeartWare’s twenty largest shareholders, recently delivered a letter to the HeartWare board of directors strongly advocating for the medical-technology company to abandon its planned purchase of Valtech, and instead consider selling itself. In the letter, Engaged Capital expressed that should the Board fail to terminate the transaction, Engaged Capital will actively campaign against the approval of the Valtech acquisition. Steve Wolosky represents Engaged Capital in its investment in HeartWare and public campaign against the Valtech transaction.